Clinical Research Directory

Inclusion Criteria: * Diagnosis of rheumatoid arthritis according to ACR/EULAR criteria * Rheumatoid Arthritis in low activity or remission according to DAS28 * Patient to receive a TOCILIZUMAB infusion 8mg/kg * Patient with failure of treatment with cDMARDs or bDMARDs * Concomitant treatment(s) for rheumatism allowed: stable doses for at least 3 months of cDMARDs, NSAIDs, analgesics, or corticosteroid therapy (\< 10 mg/day of prednisone equivalent) Exclusion Criteria: * Active neoplasia * Treatment with TOCILIZUMAB for an indication other than rheumatoid arthritis * Treatment with TOCILIZUMAB at a dosage other than 8 mg/kg * Diverticulitis or history of digestive perforation